摘要
目的探讨人结肠癌细胞系Lovo及人白血病细胞系Jurket细胞膜表面蛋白能否识别LHRH-PE40及是否存在竞争性抑制。方法将结肠癌细胞系Lovo及白血病细胞系Jurket制备成细胞膜,利用125I标记的LHRH-PE40与两种细胞膜进行放射性配基分析,与LHRH进行竞争结合分析。结果人结肠癌细胞系Lovo的结合竞争符合特异性配基-受体结合、竞争;而白血病细胞系Jurket未见配基-受体特异性结合。其中LHRH-PE40与Lovo细胞的亲和力:Kd=10·6±2·33nmol/L,容量Bmax=345±7·59pmol/mg。结论LHRH是结肠癌免疫治疗的有效靶点,LHRH-PE40对过度表达LHRH受体的结肠癌具有特异性杀伤作用,而对无LHRH表达的肿瘤无杀伤作用,对于药物的临床应用有着指导意义。
Objective To determine whether LHRH-PF40 can be indentified by the super proteinum on the surface of the eellulax membrane of the colon carcinoma cells or the leukemic cell, and to detect the competitive inhibition between them. Methods Produce the cellular membrane of the colon carcinoma cell line Lovo and the leukemic cell lines Jurket. Each of them was analyzed by radioactive ligand of LHRH-PF40 marked by ^125I and detected their competitive binding with LHRH. Results The binding of aglucone-receptor was not found in leukemic cell line. There were binding and competition of aglueone-reeeptor in colon carcinoma Lovo cells line. The cellular binding constant of Lovo was（37.82 ± 1.42） nmol· L^-1 and maximum specific binding amount was 475 ± 17.86 pmol·mg^-1 . Conclusion LHRH might be a useful target of immunotherapy in colon carcinoma.
出处
《中国实验诊断学》
2005年第6期870-872,共3页
Chinese Journal of Laboratory Diagnosis
基金
国家重点科技攻关项目(96-901-05-101)
专利申请号(9912205.9)
科学技术部科技型中小企业技术创新基金(国科发计字86号)
